ScreenPoint Medical has raised US$28 million in a Series C investment round led by Insight Partners
July 2021 — Netherlands-based ScreenPoint Medical, an AI technology company that develops advanced image recognition and machine learning software to improve early detection of breast cancer, has raised US$28 million (€24 million) in a Series C funding round led by New York-based global venture capital and private equity firm Insight Partners to further develop its technology and accelerate commercial growth of the company’s Transpara AI breast care software.
Founded in 2014 by Professor Nico Karssemeijer and Professor Sir Michael Brady and based in Nijmegen, the Netherlands, ScreenPoint Medical develops and markets innovative machine learning solutions to improve breast cancer screening and diagnosis. With its market-leading AI solution Transpara, ScreenPoint Medical supports radiologists in evaluating mammograms to detect breast cancer and allows them to improve the quality and efficiency of breast cancer screening. Transpara is currently used in over 200 clinics in 25 countries worldwide.
Insight Partners is a US-based venture capital and private equity firm with more than US$30 billion in capital commitments. With its experience and track record of investing in high-growth technology and software companies that drive transformative change in their industries, Insight Partners is ideally situated to support ScreenPoint Medical with its endeavors. Alongside Insight Partners, University Radiology Group, one of the largest providers of sub-specialty radiology and teleradiology services in the United States, participated in the investment round. Existing investors, including ScreenPoint Medical’s founders Siemens Healthineers and Oost NL, will continue to support the company in its further growth and development.
Our role in the transaction
Oaklins’ team in the Netherlands acted as the exclusive advisor to the shareholders and management of ScreenPoint Medical.
About ScreenPoint
ScreenPoint was founded in 2014 as a spin-off from Radboud University Medical Center in Nijmegen, the Netherlands, to develop and bring to market innovative machine learning solutions to improve breast cancer screening and diagnosis. With an exceptional team of specialists in machine learning, image analysis and breast imaging, ScreenPoint developed the market-leading AI solution Transpara for reading mammograms and breast tomosynthesis.
About Insight Partners
Insight Partners is a leading global venture capital and private equity firm investing in high-growth technology and software ScaleUp companies that are driving transformative change in their industries. Founded in 1995, Insight Partners has invested in more than 400 companies worldwide and has raised through a series of funds more than US$30 billion in capital commitments. Insight's mission is to find, fund and work successfully with visionary executives, providing them with practical, hands-on software expertise to foster long-term success. Across its people and its portfolio, Insight encourages a culture around a belief that ScaleUp companies and growth create opportunity for all.
Nico Karssemeijer
Founder and CEO
Talk to the deal team
Related deals
Comtax has been acquired by Ryan
Comtax, a São Paulo-based tax technology consultancy specializing in tax determination and digital tax compliance, had been acquired by Ryan, the world’s largest firm dedicated exclusively to business taxes. The transaction marks Ryan’s entry into the Brazilian market, adding a specialized team and an established base of large corporate clients in Brazil, one of the world’s most complex tax environments, at a time when the country’s consumption tax reform is set to reshape how companies calculate and report indirect taxes. For Comtax, the acquisition brings access to Ryan’s global platform, technology and client network across more than 80 countries, creating opportunities to scale its tax determination and compliance offering beyond its current footprint. Comtax’s founders will continue to lead the business.
Learn moreKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn moreNextalia has acquired a majority stake in Witapp
Nextalia SGR S.p.A. has acquired a majority stake in Witapp S.r.l., an Italian company specializing in software development for the digitization of healthcare infrastructure. The acquisition strengthens Nextalia’s track record in technology companies serving the public sector and supports its strategy of investing in businesses operating at the intersection of healthcare digitization and the modernization of public services.
Learn more